Gene Therapy
GeoVax Positions Gedeptin as Immune-Sensitizing Platform Amid Industry Shift to In Vivo Cancer Therapies
GeoVax highlights its gene-directed enzyme prodrug therapy Gedeptin as a potential immune-sensitizing platform that could enhance checkpoint inhibitor efficacy in solid tumors, aligning with rising industry investment in simplified in vivo cancer treatments.
CRISPR Gene-Editing Therapy Shows Promise in Lowering Cholesterol and Triglycerides in Phase 1 Trial
A first-in-human trial of CTX310, a CRISPR-based gene-editing therapy, demonstrated significant reductions in LDL cholesterol and triglycerides with sustained effects, potentially offering a one-time alternative to daily medications for patients with difficult-to-treat lipid disorders.
Calidi Biotherapeutics Prices $6 Million Public Offering to Advance Clinical-Stage Cancer Therapies
Calidi Biotherapeutics has priced a $6 million public offering to fund development of its Redtail platform, which uses engineered oncolytic viruses to deliver genetic medicines to metastatic cancer sites, addressing high unmet medical needs in oncology.
Creative Biolabs Enhances Gene Therapy Research with Expanded Liposomal Drug Delivery Services
Creative Biolabs has expanded its liposomal drug delivery services to support advancements in gene therapy, oncology, and molecular medicine, offering customized solutions for research institutions and pharmaceutical industries worldwide.
FDA Grants RMAT Designation to GNSC-001 for Knee Osteoarthritis Treatment
The FDA's RMAT designation for GNSC-001 highlights its potential as a groundbreaking gene therapy for knee osteoarthritis, offering long-term relief with a single injection.
Stem Cell and Gene Therapy Innovations Poised to Transform Medicine
The stem cell and gene therapy sectors are experiencing rapid growth, with innovations from companies like Adia Nutrition Inc., Mesoblast, Lineage Cell Therapeutics, and CRISPR Therapeutics leading the charge towards transformative treatments for serious diseases.
Calidi Biotherapeutics Unveils Promising Cancer Therapy Platform RTNova
Calidi Biotherapeutics has developed RTNova, an innovative gene therapy platform targeting tumors with minimal damage to healthy tissues, potentially revolutionizing cancer treatment approaches.
Tevard's tRNA Therapy Offers Promising Approach to Duchenne Muscular Dystrophy Treatment
Tevard Biosciences demonstrated a breakthrough in treating Duchenne Muscular Dystrophy by restoring full-length dystrophin protein using suppressor tRNA therapy, potentially offering hope for patients with nonsense mutations.
Calidi Biotherapeutics Unveils Promising Cancer Treatment Platform with Broad Therapeutic Potential
Calidi Biotherapeutics has demonstrated preclinical success with its RTNova platform, showing the ability to deliver gene-therapy payloads and kill over 60 tumor cell lines, potentially transforming cancer treatment approaches.
Calidi Biotherapeutics Advances Cancer Treatment with Innovative Gene Therapy Platform
Calidi Biotherapeutics has revealed promising preclinical results for its RTNova platform, offering a potential breakthrough in targeted gene therapy for cancer treatment amid rising global cancer rates.
GeoVax Presents Promising Clinical Data for Gedeptin® Gene Therapy in Head and Neck Cancer Treatment
GeoVax Labs revealed clinical trial results for Gedeptin®, a novel gene-directed prodrug therapy showing potential in treating advanced head and neck cancers with minimal side effects and stability in patient outcomes.
Tevard Advances Promising tRNA Therapy for Duchenne Muscular Dystrophy
Tevard Biosciences reports breakthrough preclinical data demonstrating a novel suppressor tRNA therapy that successfully restored dystrophin protein and motor function in a Duchenne muscular dystrophy model, potentially offering hope for patients with nonsense mutations.